SHINGRIX (Recombinant Varicella Zoster Virus Glycoprotein E antigen 50 mcg (AS01B adjuvanted vaccine)) is indicated for the prevention of herpes zoster and post-herpetic neuralgia in adults 50 years of age or older and in adults 18 years of age or older who are at increased risk of herpes zoster. SHINGRIX, a prescription medicine, is funded for people aged 65 years. From 1 July 2024, SHINGRIX is also funded for certain individuals 18 years and over at higher risk of shingles. See full funding criteria at https://schedule.pharmac.govt.nz/. Costs will apply if SHINGRIX is not funded. A single 0.5 mL dose contains 50 mcg of gE antigen, adjuvanted with AS01B (composed of the plant extract Quillaja saponaria saponin (QS-21) (50 mcg) and 3-O-desacyl-4’-monophosphoryl lipid A (MPL) from Salmonella minnesota (50 mcg) plus excipients). Dosage and administration: The primary vaccination schedule consists of two doses of 0.5 mL each; one initial dose followed by a second dose 2 to 6 months later via intramuscular injection only, preferably in the deltoid muscle. For people who are immunodeficient, immunosuppressed or likely to become immunosuppressed due to known disease or therapy, and whom would benefit from a shorter vaccination schedule, the second dose may be given 1 to 2 months after the initial dose. Contraindications: Hypersensitivity to any component of the vaccine. Precautions: Do not administer the vaccine intravascularly, intradermally or subcutaneously. Ensure medical treatment is readily available in case of an anaphylactic event following administration. Pregnancy: Category B2. There are no data on the use of SHINGRIX in pregnant women. The safety and efficacy of SHINGRIX have not been established in children and adolescents. Adverse reactions: Adults ≥50 years: pain, redness and swelling at the injection site, myalgia, fatigue, headache, shivering, fever, and gastrointestinal symptoms. In immunocompromised adult studies, there was a higher incidence of pain at the injection site, fatigue, myalgia, headache, shivering and fever in subjects aged 18 to 49 years compared with those aged 50 years and older. This is not a full list. Vaccination with SHINGRIX may not protect all vaccine recipients. Before prescribing SHINGRIX, please review the data sheet for information on dosage, contraindications, precautions, interactions and adverse effects available at www.medsafe.govt.nz. ©2025 GSK group of companies or its licensor. Trademarks are owned by or licensed to the GSK group of companies. Marketed by GlaxoSmithKline NZ Ltd, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500. For New Zealand Healthcare Professionals Only.